Medpace Holdings, Inc.

NASDAQ•MEDP

CEO: Dr. August James Troendle M.D.

セクター: Healthcare

業種: Medical - Diagnostics & Research

上場日: 2016-08-11

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

連絡先情報

5375 Medpace Way, Cincinnati, OH, 45227, United States

513-579-9911

www.medpace.com

時価総額

$12.78B

PER (TTM)

28.2

19.3

配当利回り

52週高値

$628.92

52週安値

$250.05

52週レンジ

53%

順位20Top 6.4%

6.1

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

強い • 6.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$708.45M+0.00%

直近4四半期の推移

EPS

$4.78+0.00%

直近4四半期の推移

フリーCF

$188.12M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Jumps Twenty Percent Net revenue reached $2.53B USD, marking a 20.0% increase, driven by strong activity in key therapeutic areas.

Net Income Grows Substantially Net income totaled $451.1M USD, increasing by $46.7M USD compared to the prior year results.

Backlog Conversion Strong Backlog grew 4.3% to $3.03B USD; $1.89B USD expected to convert to revenue in 2026.

New Business Awards Increase Gross new business awards totaled $2,646.8M USD, up from $2,230.0M USD in the prior year period.

リスク要因

Contract Loss Adverse Effect Potential loss, delay, or non-renewal of contracts could negatively affect operating results and revenue realization.

Margin Pressure From Inflation Operating margins face risk from increased competitive pricing pressure or continued rise of inflation impacting expenses.

Key Customer Revenue Concentration Top ten customers account for 35.1% of net revenue; loss of large customer materially affects prospects.

Cybersecurity System Failure Risk Failures in information systems like ClinTrak or security breaches could materially limit operations and harm reputation.

見通し

Strategy Focus CRO Market Aim to expand market share in growing Phase I-IV CRO market, focusing on Oncology and CNS areas.

Talent Acquisition Critical Attracting, developing, and retaining qualified professional and scientific staff is key component for sustaining organic growth.

Funding Operations Growth Expect existing cash, operating cash flow, and potential borrowings to fund operational growth and acquisitions.

Capital Spending Moderates Capital spending as percentage of revenue decreased 49 basis points to 1.24% for the fiscal year 2025.

同業比較

売上高 (TTM)

CNC

$194.78B

+19.4%

FMS

$22.15B

+1.5%

THC

$21.31B

+3.1%

粗利益率 (最新四半期)

NBIX

97.8%

-0.5pp

COO

67.9%

-10.1pp

ILMN

67.0%

-1.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
DGX	$22.22B	22.3	13.9%	42.6%
THC	$20.01B	14.2	34.8%	44.4%
ILMN	$18.19B	21.4	34.9%	38.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

8.2%

安定成長

4四半期純利益CAGR

5.6%

収益性の着実な向上

キャッシュフロー安定性

100%

優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月20日

EPS:$3.74

売上高:$697.98M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし